Clearside Biomedical Inc. (CLSD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Clearside Biomedical Inc. (CLSD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.93

0.01 (1.09%)

At close: Jan 15, 2025, 11:49 AM

undefined% (undefined)

Bid	0.93
Market Cap	70.82M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.45
PE Ratio (ttm)	-2.08
Forward PE	n/a
Analyst	Buy

Ask	0.94
Volume	61,536
Avg. Volume (20D)	338,380
Open	0.92
Previous Close	0.92
Day's Range	0.91 - 0.94
52-Week Range	0.80 - 2.12
Beta	undefined

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an i...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 2, 2016

Employees 30

Stock Exchange NASDAQ

Ticker Symbol CLSD

Website https://www.clearsidebio.com

Analyst Forecast

According to 6 analyst ratings, the average rating for CLSD stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 488.99% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Clearside Biomedical Inc. is scheduled to release its earnings on Mar 11, 2025, during market hours.
Analysts project revenue of $294.43K, reflecting a -95.36% YoY shrinking and earnings per share of -0.11, making a 37.50% increase YoY.

Why Price Moved

6 months ago · Source

+15.74%

Clearside Biomedical shares are trading higher aft... Unlock content with Pro Subscription

8 months ago · Source

-7.41%

Clearside Biomedical shares are trading lower after the company reported worse-than-expected Q1 financial results.

News

1 month ago · zacks.com

Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now

Clearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

2 months ago · zacks.com

All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · seekingalpha.com

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jenny Kobin - IR George Lasezkay - CEO Victor Chong - Chief Medical Officer...

2 months ago · zacks.com

Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago.